Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Study summary

The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSCH66336

The study team can explain what participation involves.

Who it may be forMyelogenous Leukemia, Chronic

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 30, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?M.D. Anderson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Interventions being studied: Drug: SCH66336

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated phase;
Failure to respond to or intolerance to imatinib mesylate (Gleevec);
Age \>/= 16 years;
Life expectancy of \>/= 2 months;
Performance status 2 or better (Zubrod);
Adequate renal and hepatic functions (creatinine and bilirubin \</= 2 mg/dl);
Adequate cardiac function;
Not candidates for or have refused allogeneic transplantation;
Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole), macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs (phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

MDAnderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 30, 2018. Always confirm current availability with the study team.

View original record ↗